What 4 Analyst Ratings Have To Say About Ligand Pharmaceuticals
What 4 Analyst Ratings Have To Say About Ligand Pharmaceuticals
關於ligand pharmaceuticals公司的分析師評級有哪些？
4 analysts have expressed a variety of opinions on Ligand Pharmaceuticals (NASDAQ:LGND) over the past quarter, offering a diverse set of opinions from bullish to bearish.
過去一個季度，有4個分析師對Ligand Pharmaceuticals (納斯達克:LGND) 表達了不同的看法，其中觀點從看好到看淡不一。
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
下表提供了分析師最近的評級概述，爲了全面了解過去30天的情緒變化並與前幾個月進行比較，提供了深入的見解。
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $119.5, with a high estimate of $144.00 and a low estimate of $95.00. This current average has decreased by 6.4% from the previous average price target of $127.67.
分析師對未來12個月價格目標的評估提供了額外的信息，展示了平均目標價119.5美元，最高估價144.00美元，最低估價95.00美元。當前平均價格目標較上一個平均價格目標127.67美元下降了6.4%。
Deciphering Analyst Ratings: An...
分析師評...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。